Blueprint Medicines Upsizes IPO Amid Cancer Biotech Craze
Venture capital-backed Blueprint Medicines Corp., led by Goodwin Procter LLP, priced an upsized initial public offering Wednesday evening to raise nearly $147 million, beating expectations as investors vie for shares in...To view the full article, register now.
Already a subscriber? Click here to view full article